+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Absence of antibody against human papillomavirus type 16 E6 and E7 in patients with cervical cancer is independent of sequence variations



Absence of antibody against human papillomavirus type 16 E6 and E7 in patients with cervical cancer is independent of sequence variations



Journal of Infectious Diseases 181(5): 1764-1767



It is not known whether the lack of antibody response against human papillomavirus (HPV) type 16 E6 and E7 among some cervical cancer patients is due to naturally existing sequence variations. In this study, naturally occurring HPV-16 E6 and E7 variants (including the prototype) were cloned, antigens were expressed by in vitro transcription and translation, and the humoral immune response of 34 HPV-16-positive cervical cancer patients was analyzed by radioimmunoprecipitation assay (RIPA). In addition, the RIPA results were compared with those of a sandwich-protein ELISA, to further substantiate antibody status. Sera lacking E6 reactivity by RIPA remained negative by protein ELISA. All E6 antigens (the prototype and the variants 350G¿L83V, 131G¿R10G/350G¿L83V, 335T¿H78Y/350G¿L83V, 345G¿Y81C/350G¿L83V, and African 2 ¿Af2) showed cross-reactivity by RIPA. The lack of HPV-16 E6 or E7 antibodies is independent of naturally occurring variants in cervical cancer patients. Thus, testing for HPV-16 E6 or E7 prototype antigens seems to be sufficient in serological assays.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 010112307

Download citation: RISBibTeXText

PMID: 10783118

DOI: 10.1086/315451


Related references

Occurrence of the antibody against human papillomavirus type 16 virion protein L2 in patients with cervical cancer and dysplasia. Intervirology 38(3-4): 187-191, 1995

Serum antibody against unfused recombinant E7 protein of human papillomavirus type 16 in cervical cancer patients. Japanese Journal of Cancer Research 86(1): 28-34, 1995

Human papillomavirus type 16 E6 and E7 gene variations in Indian cervical cancer. Gynecologic Oncology 87(3): 268-273, 2002

Sequence polymorphism of human papillomavirus type 16 E7 in cervical cancer. Di 1 Jun Yi Da Xue Xue Bao 25(10): 1272-1275, 2005

Independent association of antibodies against human papillomavirus type 16 E1/E4 and E7 proteins with cervical cancer. Virology 190(2): 724-732, 1992

Induction of human papillomavirus-specific CD4(+) and CD8(+) lymphocytes by E7-pulsed autologous dendritic cells in patients with human papillomavirus type 16- and 18-positive cervical cancer. Journal of Virology 73(7): 5402-5410, 1999

Human papillomavirus type 16 E6 and E7 gene variations associated with cervical cancer in a Han Chinese population. Infection Genetics and Evolution 73: 13-20, 2019

The association of human papillomavirus type 16 E2 variations with cervical cancer in a Han Chinese population. Infection Genetics and Evolution 64: 241-248, 2018

Genome organization and nucleotide sequence of human papillomavirus type 33, which is associated with cervical cancer. Journal of Virology 58(3): 991-995, 1986

A vaccine conjugate of 'ISCAR' immunocarrier and peptide epitopes of the E7 cervical cancer-associated protein of human papillomavirus type 16 elicits specific Th1- and Th2-type responses in immunized mice in the absence of oil-based adjuvants. Clinical and Experimental Immunology 101(2): 265-271, 1995

Detection of E2 gene polymorphism of human papillomavirus type 16 in patients with cervical lesions and cervical cancer. Nan Fang Yi Ke Da Xue Xue Bao 32(10): 1503-1506, 2012

Follow-up of antibody responses to human papillomavirus type 16 E7 in patients treated for cervical carcinoma. Journal Of Medical Virology. 45(3): 342-347, 1995

Utilization of the human genome sequence localizes human papillomavirus type 16 DNA integrated into the TNFAIP2 gene in a fatal cervical cancer from a 39-year-old woman. Clinical Cancer Research 8(2): 549-554, 2002

Sequence variation and physical state of human papillomavirus type 16 cervical cancer isolates from Australia and New Caledonia. International Journal of Cancer 97(6): 868-874, 20 February, 2002

The prognostic role of serologic testing for antibody production against human papillomavirus type 16 E6 and E7 oncogenes in cervical cancer. Gynecologic Oncology 56(1): 138, 1995